Cargando…
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
OBJECTIVE: Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. We quantitively...
Autores principales: | Janowitz, Tobias, Gablenz, Eva, Pattinson, David, Wang, Timothy C, Conigliaro, Joseph, Tracey, Kevin, Tuveson, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299656/ https://www.ncbi.nlm.nih.gov/pubmed/32499303 http://dx.doi.org/10.1136/gutjnl-2020-321852 |
Ejemplares similares
-
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
por: Brennan, Christina M, et al.
Publicado: (2022) -
Incidence of thrombotic complications in hospitalised and non‐hospitalised patients after COVID‐19 diagnosis
por: Tholin, Birgitte, et al.
Publicado: (2021) -
Cardiac complications in patients hospitalised with COVID-19
por: Linschoten, Marijke, et al.
Publicado: (2020) -
Impact of COVID-19 restrictions on hospitalisation and post-operative rehabilitation of head and neck cancer patients
por: Crosetti, Erika, et al.
Publicado: (2021) -
Hospitalisation rate and mortality among people with and without diabetes during the COVID-19 pandemic year 2020
por: Narres, Maria, et al.
Publicado: (2022)